Arcutis Biotherapeutics (id:7845 ARQT)

10.14 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 10:00:05 AM)

Exchange closed, opens in 23 hours 29 minutes

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Arcutis Biotherapeutics

Market Capitalization 1.10B

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.